Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2307

Sigma-Aldrich

Lodoxamide

≥98% (HPLC)

Synonym(s):

2,2′-[(2-Chloro-5-cyano-1,3-phenylene)diimino]bis-2-oxoacetic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H6ClN3O6
CAS Number:
53882-12-5
Molecular Weight:
311.63
MDL number:
MFCD00864803
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to very dark brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

InChI

1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)

InChI key

RVGLGHVJXCETIO-UHFFFAOYSA-N

Biochem/physiol Actions

Lodoxamide Tromethamine is a potent agonist of GPR35 in both human and rat, and an antiallergic mast cell stabilizer used clinically in the UK for treatment of allergic conjunctivitis.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Amanda E MacKenzie et al.
Molecular pharmacology, 85(1), 91-104 (2013-10-12)
Lack of high potency agonists has restricted analysis of the G protein-coupled receptor GPR35. Moreover, marked variation in potency and/or affinity of current ligands between human and rodent orthologs of GPR35 has limited their productive use in rodent models of
Soo-Jin Park et al.
British journal of pharmacology, 175(1), 154-161 (2017-10-27)
GPR35 has long been considered an orphan GPCR, because no endogenous ligand of GPR35 has been discovered. CXCL17 (a chemokine) has been reported to be an endogenous ligand of GPR35, and it has even been suggested that it be called
Alejandro Rodriguez-Garcia et al.
International ophthalmology, 38(3), 1243-1249 (2017-06-12)
To report the therapeutic efficacy and safety of topical 0.1% lodoxamide in the long-term treatment of superior limbic keratoconjunctivitis. Sixty-seven eyes of 34 patients with active SLK were studied. Therapeutic response was analyzed according to modified-Ohashi parameters. All eyes were

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service